tiprankstipranks
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
PremiumThe FlyCognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
27d ago
Cognition Therapeutics Reports Promising Q3 2024 Results
Premium
Company Announcements
Cognition Therapeutics Reports Promising Q3 2024 Results
1M ago
Cognition Therapeutics reports Q3 EPS (25c), consensus (22c)
Premium
The Fly
Cognition Therapeutics reports Q3 EPS (25c), consensus (22c)
1M ago
Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders
PremiumCompany AnnouncementsCognition Therapeutics Highlights CT1812 Potential in CNS Disorders
3M ago
Cognition Therapeutics Shares Investor Presentation Update
Premium
Company Announcements
Cognition Therapeutics Shares Investor Presentation Update
4M ago
Cognition Therapeutics announces results from the SEQUEL study of CT1812
Premium
The Fly
Cognition Therapeutics announces results from the SEQUEL study of CT1812
4M ago
Cognition Therapeutics price target lowered to $5 from $6 at Ladenburg
PremiumThe FlyCognition Therapeutics price target lowered to $5 from $6 at Ladenburg
5M ago
Cognition Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Cognition Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
5M ago
Cognition downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Cognition downgraded to Neutral from Overweight at Cantor Fitzgerald
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100